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ContractilityCalciumhas beenunequivocally regarded as a key signalmessenger in almost every cell type. Calcium regulates a
number of important cellular functions including cell growth, myoﬁlament contraction, cell survival and
apoptosis as well as gene transcription. A complex regulatory mechanism of cellular calcium is needed to ﬁne
tune the precise calcium concentration in each subcellular location and also to transmit the signals carried by the
calcium pool to the correct end target. In this article we will review the recently emerging role of the plasma
membrane calcium/calmodulin dependent ATPase isoform 4 (PMCA4) in regulating calcium signalling. We will
then focus on the function of this molecule in cardiomyocytes, in which PMCA4 forms protein–protein
interactions with several key signalling molecules. Recent evidence has shown in vivo physiological
functionalities and possible clinical implications of the PMCA4 signalling complex. This article is part of a Special
Issue entitled: 11th European Symposium on Calcium.almodulin dependent ATPase;
CA, secretory pathway calcium
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Calcium is central in the regulation of a large number of fundamental
cellular physiological functions. In most cell types intracellular calcium
ishighlydynamic, for example in cardiomyocytes calciumconcentration
ﬂuctuates from a resting diastolic level of 100 nM to a peak systolic level
of 1 μM [1,2]. Calcium travels throughout subcellullar compartments
whilst transmitting signals that are key for cell functions, such as
myoﬁlament contraction, gene transcription, cell growth and even cell
death or apoptosis. Variations in its concentration (amplitude),
frequencyof the oscillations and spatial locationsdetermine the calcium
signals [3]. These signals will be decoded by the effectors, usually these
are calcium/calmodulin binding proteins, which will translate the
signals to some speciﬁc actions, such as enzymatic activity, protein
binding and conformational changes.The complexity of calcium signal coding and decoding processes are
accurately controlled by a set of proteins that not only regulate
intracellular calcium ﬂux, but also direct the signal to its precise target
molecules. The calciumATPases (also known as calciumpumps) are the
chief players in this matter (reviewed in [2]). These pumps are
membrane bound and therefore are responsible for transporting the
ion across the membrane. Three types of this pump have been
recognised according to their localization: i) plasmamembrane calcium
ATPase = PMCA; ii) sarcoplasmic reticulum ATPase (SERCA) and
iii) secretory pathway ATPase (SPCA), which is located at the Golgi
membrane. Our focus in this paper is isoform 4 of the PMCA (PMCA4),
which is expressed in all cell types [4]. In particular we will review the
role of PMCA4 in cardiomyocytes, where it precisely controls the
calcium signals to ensure they reach the correct destination (target/
effector) in the right strength (amplitude/frequency).2. Protein binding domains are vital in PMCA4
In cardiomyocytes PMCA4 is localized in the caveolae [5,6],
traditionally known as a hub of the signals that cross the plasma
membrane. A large number of signalling molecules are situated in this
sub-cellular compartment and understandably a considerable amount
of molecular signal including calcium may reach caveolae [7]. In this
regard PMCA4 displays its key role: selecting the target for the calcium
signal. As a calciumATPase, PMCA4 has a high afﬁnity with calcium and
in addition to that feature, PMCA4 interacts with a number of key
signallingmolecules [8], enabled by the fact that PMCA4 containsmany
protein binding domains.
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which are responsible for key interactions with potential targets of
calcium signalling including the PDZ binding domain, large intracel-
lular loop and the N-terminal tail (Table 1).
2.1. PDZ binding domain
PDZ domains were ﬁrst identiﬁed in the postsynaptic density
protein (PSD95) [9], Drosophila homologue discs large tumour
suppressor (DlgA) [10] and zonula occludens-1 (ZO1), a tight-
junction protein [11]. These domains containing approximately 80–
90 amino acids that act as scaffolds for protein–protein interactions
[12,13]. The PDZ domain interaction is a speciﬁc type of interaction
module bearing a structurally well-deﬁned interaction “pocket” that
can be ﬁlled by a PDZ motif ‘ligand’ [14]. These ligands are consensus
sequences that are normally, but not always [15], located at the
extreme intracellular carboxyl terminus [16]. Four types of PDZ
domain motifs have been classiﬁed: type I (S/T-x-Φ), type II (Φ-x-Φ),
type III (Ψ-x-Φ) and type IV (D-x-V), where x is any amino acid,Φ is a
hydrophobic amino acid (V, I, L, A, G,W, C, M, F) and Ψ is a basic,
hydrophilic amino acid (H, R, K) [16].
Most partners for PMCA have been found to interact with a PDZ
ligand in the C-terminal region especially of isoforms 4b of the pump.
The carboxy terminal tail of the human PMCA1b, -2b, and -3b indeed
contain a PDZ-ligand motif -ETSL*, whereas hPMCA4b carries a more
perfect motif –ETSV*. The ﬁrst identiﬁed PDZ interaction partners of
PMCA are the members of the MAGUK (membrane-associated
guanylate kinase) family of kinases, a PDZ-domain containing protein
family [17]. More interesting is the ﬁnding that PMCA4b interacts
with neuronal nitric oxide synthase (nNOS) [18] (the only NOS
isoform that structurally contain a PDZ domain) [19]. Another PDZ-
mediated interaction partner of PMCA4 is the calcium/calmodulin-
dependent serine protein kinase (CASK) which is another MAGUK
protein and a co-activator of the transcription of T-element containing
promoters. This interaction has been found in brain and kidney
tissues. Functionally, overexpression of PMCA4b down-regulates the
T-element-dependent reporter activity which is CASK dependent [20].
As was suggested for nNOS, the negative regulation of CASK by PMCA4
could be the result of Ca2+ depletion in close proximity to the enzyme.
Other structural PDZ interactions have been demonstrated for
PMCA4b isoform. These include the PMCA-interacting single-PDZ
domain (PISP), a ubiquitously expressed protein, which through its
interaction with PMCA4 inﬂuences their localisation to the plasma
membrane [21]. PMCA4b and Ania-3 also bind via PDZ interaction.Table 1
Interaction partners of PMCA4 and the possible functions.
Binding domain Interaction partners Cell types/t




PDZ-binding domain nNOS (neuronal nitric oxide synthase) HEK293, ne
PDZ-binding domain CASK (calcium/calmodulin-dependent
serine protein kinase)
Brain, kidne
PDZ-binding domain PISP (PMCA-interacting single-PDZ domain) MDCK cells
PDZ-binding domain Ania-3 MDCK cells
neurons
PDZ-binding domain CLP36 Platelets
Calmodulin binding site Calmodulin Puriﬁed pro
Main intracellular loop RASSF1A (Ras-association domain
family protein member 1A)
HEK293 an
cardiomyoc
Main intracellular loop alpha-1 syntrophin HEK293 cel
Main intracellular loop Calcineurin A HEK293 cel
N-Terminal 14-3-3 HeLa cellsAnia3 is a member of the Homer family of scaffolding proteins that
couple NMDA (N-methyl-D-aspartate) receptors in the brain and link
extracellular signals to Ca2+ release from intracellular stores [22]. The
interaction between Ania-3 and PMCA4 may represent a novel
mechanism by which local calcium signalling and hence synaptic
function can be modulated in neurons, however further studies are
needed to clarify the functionality of this interaction [22]. The most
recently discovered PDZ-mediated interaction partner of PMCA4b is
CLP36 (C-terminal LIM domain protein), a protein that interacts with
the actin cytoskeleton in platelets. This interaction has been found to
be involved in CLP36 translocation during platelet activation [23].
2.2. Calmodulin binding site
The calmodulin binding domain is located at the C-terminal loop of
PMCA4. It plays a crucial role in regulating the pump activity. The
binding of calmodulin to this site (located approximately 40 amino
acid residues downstream of the last transmembrane domain) [24]
releases the inhibitory effect caused by the binding of the C-terminal
to the large cytosolic loop which contains the major catalytic unit
between the phosphorylation and the ATP binding site [25].
2.3. Main intracellular loop
The largest intracellular loop of PMCA is located between trans-
membrane domains 4 and 5. This loop contains catalytic sites
including the ATP binding site and the aspartate residue which is
phosphorylated during the calcium transport cycle [26]. The main
intracellular loop of PMCA4 has been found to have several functional
interactions with signalling proteins as well as structural/adaptor
proteins. These interaction partners include the tumour suppressor
Ras-association domain family protein isoform 1A (RASSF1A) [27], α1
syntrophin [28] and calcineurin [29].
2.4. N-terminal region
The N-terminal region of PMCA has a very low degree of sequence
homology amongst isoforms, and thus is the region commonly used to
raise isoform speciﬁc antibodies. Isoform ε of 14-3-3 protein interacts
with PMCA4 and functionally inhibits the ability of PMCA4 to eject
calcium [30]. Isoform ε of 14-3-3 protein is the ﬁrst identiﬁed
inhibitory partner for PMCA4. This molecule also interacts with
PMCA1 and PMCA3 and similar to the interaction with PMCA4, 14-3-3
protein also inhibits PMCA1 and PMCA3 activity [31].issues investigated Function References
Unknown [17]
uro-2a and heart Regulation of nNOS activity,
cardiac β-adrenergic response and
cardiac hypertrophy
[18,34,36]
y and HEK293 cells Regulation of T-element-dependent
reporter (Tbr-1) activity
[20]
Sorting PMCA4 to or from the
plasma membrane
[21]
and hippocampal Synaptic function [22]
Translocation during platelet activation [23]
tein PMCA activation [25]
d primary rat
ytes
Regulation of Ras-MAPK signalling pathway [27]
ls and heart Regulation of nNOS activity [28]
ls and heart Regulation of calcineurin activity and
cardiac hypertrophy
[29,35]
Regulation of PMCA activity [30]
Fig. 1. Schematic model of the PMCA4 signalling network. Grey lines indicate physical
interaction; red arrows indicate functional regulation. DLG4, disc large homolog
4: member of membrane-associated guanylate kinase (MAGUK) family, also known as
PSD95; CAPON, C-terminal PDZ domain ligand of neuronal nitric oxide synthase; nNOS,
neuronal nitric oxide synthase; CASK, calcium/calmodulin-dependent serine protein
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In cardiomyocytes intracellular calcium concentrations swing
greatly. It is believed that the majority of the calcium pool is used
for activating the myoﬁlaments and contractile molecules, and hence
most of the calcium transporters expressed in the cardiomyocytes are
dedicated to the excitation–contraction coupling process [32].
However, recent ﬁndings have indicated that a subset of calcium in
the cardiomyocytes is used as a molecular signal messenger, notably
in the regulation of cell growth and survival [33]. This ﬁnding has
raised a question whether the calcium pool used for signalling is
distinct from that used for excitation–contraction coupling and hence
whether there is a transporter speciﬁcally involved in regulating
calcium signalling that is exempt from excitation–contraction
coupling duties.
Over a number of years we have investigated the idea that PMCA4
is the calcium pump responsible for regulating calcium signalling in
the heart and is not involved in excitation–contraction coupling.
Indeed, we and others have shown that the contribution of PMCA4 to
excitation–contraction coupling is very minor [34,35]. Furthermore, a
molecular signalling network, located at the caveolae in the
cardiomyocytes, with PMCA4 as the focal point has been discovered
involving major signalling molecules such as nNOS, RASSF1A,
calcineurin and α1-syntrophin [27–29].kinase; Nav1.5, sodium channel, voltage-gated, type V; RASSF1A, Ras-association
domain protein family member 1A.3.1. PMCA4/nNOS/α1-syntrophin signalling complex
We ﬁrst hypothesized a physical interaction between PMCA4 and
nNOS through a bioinformatics analysis of PDZ-domain carrying
proteins that are located in caveolae, and conﬁrmed using GST-pull
down assays and immunoprecipitation analyses using HEK-293 cells
overexpressing PMCA4 and nNOS [18]. Further analyses have shown
this interaction in brain and heart tissue extracts as well as isolated
cardiomyocytes [28]. The interaction is likely through the PDZ domain
of nNOS and the PDZ ligand at the C-terminus of PMCA4 since deletion
of these domains and capping of the PDZ ligand ablated the
interaction [18]. More interestingly, we found a functional implication
of this interaction both in the HEK293 model and in cardiomyocytes:
overexpression of PMCA4 reduced nNOS enzymatic activity, which is
somewhat logical because nNOS is a calcium/calmodulin dependent
enzyme and PMCA4 will deplete calcium from its local vicinity. This
idea was supported by the data that a defective mutant of PMCA4,
which is unable to pump calcium, failed to inhibit nNOS activity
despite interacting with it [18,28].
The complexity of PMCA4/nNOS signalling module was enhanced
when we found that PMCA4 interacts with α1-syntrophin. This
interaction was ﬁrst discovered using a bacterial two hybrid screen
with the large internal loop of PMCA4 acting as a bait, the interaction
was then conﬁrmed by immunoprecipitation of the proteins in both a
cellular model as well as in heart tissue [28]. Although α1-syntrophin
also contains PDZ domain, the interaction with PMCA4 is not PDZ-
mediated. The linker between the Plekstrin homology 2 (PH2) and SU
domains of α1-syntrophin was found to be responsible for binding
with the intracellular loop between transmembrane domains 4 and 5
of PMCA4 [28]. Based on the fact that α1-syntrophin interacts with
nNOS via a PDZ domain it seems that these three molecules may form
a signalling network. This was supported by the ﬁnding that α1-
syntrophin overexpression enhances the inhibitory effect of PMCA4
on nNOS [28].
By including other interaction partners of nNOS and α1-syntrophin
that are present in cardiomyocytes (such as the adaptor molecule
CAPON,dystrophin and sodiumchannelNav1.5) a largernetwork canbe
modelled (Fig. 1). This network regulates at least two major
physiological processes in the heart: the β-adrenergic contractile
response and cardiac rhythm.3.1.1. Modulation of beta adrenergic signal
Transgenic overexpression of PMCA4 in the mouse heart signiﬁ-
cantly reduced the β-adrenergic contractile response, although it did
not change the calcium transient [34,36]. This phenotype was
attributable to the interaction of PMCA4 with and modulation of
nNOS function as demonstrated by the ﬁnding that overexpression of
mutant PMCA4 that did not bind to nNOS (PMCA4 ct120) did not
produce a similar phenotype [34]. Systematic molecular analyses using
both isolated cardiomyocytes and transgenic mouse hearts revealed a
novel pathway downstream of the PMCA4/nNOS complex that is
responsible for controlling the cardiac β-adrenergic response. PMCA4
bound nNOS is responsible for cGMP production likely through
modulationof soluble guanylyl cyclase. At themembranecGMPcontrols
the level of cAMP by modulating the activity of the phosphodiesterases
PDE2 and PDE3 [36]. As cAMP is a central part in transmitting the
β-adrenergic signals via protein kinase A, reduction in the level of this
cyclic nucleotide would signiﬁcantly reduce contractility in response to
β-adrenergic agonists.
3.1.2. Modulation of QT duration
The other functional role of the PMCA4/nNOS/α1-syntrophin
complex has been underscored by the ﬁnding that the A390V point
mutation in the α1-syntrophin gene, which is located in the region
responsible for the binding with PMCA4 is associated with long QT
syndrome [37]. Long QT syndrome is a condition characterized by
prolonged ventricular repolarization and is strongly related with
syncope and sudden death due to cardiac arrhythmia. Analysis of the
pathological consequences of the A390V mutation has revealed that
this mutation enhances nNOS activity possibly due to the release of
PMCA4 from the complex, since the A390V mutant α1-syntrophin
failed to form an interaction with PMCA4 [37]. Increased nNOS
activity would then inactivate the voltage gated sodium channel
Nav1.5, likely through the process of nitrosylation. This mechanism
explains the prolonged QT duration caused by the A390V mutation in
α1-syntrophin.
An additional line of evidence underlining the importance of the
PMCA4/nNOS/α1-sytntrophin complex in regulating QT duration came
from a recent genomewide association study (GWAS) showing that an
SNP in CAPON is associated with long QT duration and sudden death
Stimuli: adrenergic agonist,
shear stress, etc 
Ca2+
Responsefrom










Fig. 2. Amodel of the regulation of a local calcium pool by PMCA4 in the context of signalling in cardiomyocytes. PMCA4 regulates the activity of the end target of calcium signalling
by: (i) maintaining local calcium concentration and (ii) transmitting the calcium pool for signalling to its interaction partners.
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study has demonstrated that CAPON expression in cardiomyocytes
stabilizes nNOS, which leads to the inhibition of the L-type calcium
channel and hence will accelerate cardiomyocyte repolarization [40].
However, it remains to be seen towhat extent PMCA4 is involved in this
process.
3.2. PMCA4/RASSF1A/Calcineurin complex and the modulation of cardiac
hypertrophy
The largest intracellular loop of PMCA4 (between transmembrane
segments 4 and 5) plays a more signiﬁcant role as an interacting
domain than previously expected. Two molecules that are important
in regulating cardiac hypertrophy: the tumour suppressor molecule
RASSF1A and calcineurin form complexes with PMCA4 through
interaction at this domain. RASSF1A has been described as a powerful
inhibitor of cardiac hypertrophy [41] and we have shown that PMCA4
expression could enhance the inhibitory effect of RASSF1A on the pro-
hypertrophic Ras-MAPK pathway [27].
The interaction with calcineurin also has signiﬁcant functional
implications. Calcineurin is a bona ﬁde upstream activator of the NFAT
transcription factor, which is the key pathway in the regulation of
cardiac hypertrophy. We have found that ectopic expression of
PMCA4 inhibited calcineurin [29] and hence reduced the activation of
NFAT. Using transgenic mice overexpressing PMCA4 Wu et al. have
shown the in vivo relevance of the inhibitory action of PMCA4 on
calcineurin/NFAT pathway, by demonstrating that PMCA4 protects
against the development of pressure-overload induced hypertrophy
[35].
4. Mechanism of signal control and transduction by PMCA4
Several lines of evidence as outlined above suggest that in
modulating the β-adrenergic response, QT duration or the response
against hypertrophic stimuli, PMCA4 has a crucial role as a key regulator
of calciumsignal transmission to the targetmolecules, for examplenNOS
and calcineurin. In response to various stimuli (e.g. action potential, β-
adrenergic agonist, mechanical stretch), intracellular calcium amplitudeas well as oscillation frequency are increased and since nNOS and
calcineurin are calcium dependent, their activities would be increased.
Hence the downstream effectors: e.g. the NO dependent calcium
handling proteins (for nNOS) and the NFAT pathway (for calcineurin)
will be activated. In this setting PMCA4 may regulate and prevent overt
activation of these targets of the calcium signal (Fig. 2).
The other crucial role of PMCA4 in local calcium signalling is to
make sure that the signal reaches the correct destination, i.e. by
performing protein–protein interactions. This hypothetical mecha-
nism will be difﬁcult to examine using the gain of function or
overexpression model. Therefore the precise role of PMCA4 may be
further deﬁned by analysing knock out or knock downmodels as well
as using a speciﬁc inhibitor. It is also essential that we further
understand how a local calcium signal is regulated by a molecule like
PMCA4. The recent development of genetically encoded calcium
indicators and imaging technologies [42] may provide a novel
approach to investigate the role of PMCA4 in the regulation of local
calcium concentrations. Given the importance of PMCA4 in many key
processes in the heart the discovery of a novel PMCA4 inhibitor would
provide an important tool to help unravel the exact functions of
PMCA4. In addition, the inhibitor can also become a tool to look at the
effect of interfering local calcium signal in the sarcolemma.5. Conclusion
PMCA4 plays a pivotal role in the regulation of the calcium signal
in cardiomyocytes. Molecular interactions, notably with nNOS and
calcineurin, appear to be the key aspect during the calcium signal
transduction and signal targeting by PMCA4. Recent studies using
genetically modiﬁed mice have clearly demonstrated the in vivo
functionality of this signalling complex. Furthermore, genome wide
association analyses also suggest possible clinical implications of
mutations or polymorphisms in the PMCA4 protein complex.
In the future the development of speciﬁc agents, which can
regulate the function of PMCA4 and in wider context the local calcium
signal governed by PMCA4, may provide a novel therapeutic approach
to the cardiovascular diseases.
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